Related Experiment Videos
[Sentinel node study with patent blue in cervical cancer]
Sabas Carlos Vieira1, Luiz Carlos Zeferino, Benedito Borges da Silva
1Departamento de Clínica Geral, Universidade Federal do Piauí e Hospital São Marcos, Teresina, PI. sabasmarcia@uol.com.br
Revista Da Associacao Medica Brasileira (1992)
|October 23, 2004
Summary
Sentinel lymph node identification using patent blue dye is feasible in patients with invasive cervix cancer. Further research is needed to establish its role in treatment planning for cervical cancer.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Nuclear Medicine
Background:
- Cervical cancer staging often involves pelvic lymphadenectomy.
- Sentinel lymph node biopsy (SLNB) is a minimally invasive staging technique.
- Accurate lymph node assessment is crucial for treatment planning in cervical cancer.
Purpose of the Study:
- To assess the feasibility of intraoperative lymphatic mapping for sentinel node identification.
- To evaluate the utility of patent blue dye in detecting sentinel nodes in patients with invasive cervical cancer.
Main Methods:
- Fifty-one patients with FIGO Stage I and II cervical cancer underwent radical hysterectomy and pelvic lymphadenectomy.
- Patent blue V dye was injected circumferentially around the tumor prior to surgery.
- Lymph nodes exhibiting dye uptake during pelvic lymphadenectomy were identified as potential sentinel nodes.
Main Results:
- Sentinel nodes were successfully identified in 32 out of 51 patients (62.7%).
- The study observed four false-negative cases.
- Performance metrics included: specificity 38.6%, sensitivity 42.8%, positive predictive value 10%, and negative predictive value 80.9%.
Conclusions:
- Sentinel lymph node identification using patent blue dye is technically feasible in the context of cervical cancer surgery.
- Larger patient cohorts are necessary to validate sentinel node detection rates and refine its application in cervical cancer therapy and staging.